BioSpace News Archive

Mannatech, Incorporated today announced financial results for its second quarter of 2022.

Bruker Corporation announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock.

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer.

Aptinyx Inc. today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.

GreenLight Biosciences today announced a private placement of approximately $109 million.

Ocugen, Inc announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17.

Mind Medicine today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal , effective August 11, 2022 as independent members of its Board of Directors.

Soligenix, Inc. announced today its recent accomplishments and financial results for the quarter ended June 30, 2022.

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announced financial results for the second quarter ended June 30, 2022 and provided a business update.

An in-depth article authored by Florida Cancer Specialists & Research Institute, LLC pharmacy experts published in the American Journal of Managed Care® issues a call to action for the development of improved metrics to help lower costs and better assess the performance of pharmacies that dispense oral oncolytic medications.